Newsroom > In the News
In the news
News headlines are articles that reference ResMed's company, people, or business practices.
May 21, 2017MedPage Today
Patients with persistent hypercapnia following an acute exacerbation of chronic obstructive pulmonary disease (COPD) had a longer time to death or rehospitalization if non-interventional ventilation was added to their home oxygen therapy, researchers found.
For Patients With Treatment-emergent Central Sleep Apnea, Switching from CPAP to ASV Significantly Improves ComplianceMay 16, 2017Sleep Review
ResMed Inc announced that people with obstructive sleep apnea who develop central sleep apnea (CSA) are more compliant on therapy after they switch from continuous positive airway pressure (CPAP) therapy to adaptive servo-ventilation (ASV) therapy, according to the largest-ever analysis of patients with treatment-emergent CSA.
May 8, 2017Becker's Hospital Review
Amy Cook, Director of Healthcare Informatics at ResMed, was named to Becker's list of 110 Women in Medtech to Know in 2017. Joining ResMed in 2012, she was integral in developing and rolling out the company's suite of connected health IT services and platforms.
S+, Setting a New Standard in Consumer and Clinical Sleep Technology: Interview with Colin Lawlor, CEO of SleepScore LabsMay 3, 2017Medgadget
The S+ platform is the newest technology disrupting the $60B consumer sleep industry. Developed by SleepScore Labs, a joint venture between ResMed, a 25-year leader in prescription sleep medical devices, Dr. Mehmet Oz, and Pegasus Capital Advisors, the S+ is a clinical grade, non-prescription, non-contact sleep monitoring device coupled with a mobile app.
April 25, 2017San Diego Union-Tribune
Instead of packing up their larger, bedside machines from home for a trip, sleep apnea patients can travel with a much smaller device, according to the company. It’s akin to taking a tablet on the road while leaving the desktop computer at home, said ResMed Chief Executive Michael “Mick” Farrell.